Welcome to our dedicated page for Ibio SEC filings (Ticker: IBIO), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
iBio, Inc. filings document material events for an AI-driven biotechnology company developing precision antibody therapies. Recent Form 8-K disclosures cover clinical and regulatory updates for IBIO-600, preclinical data for IBIO-610, quarterly financial results, Regulation FD communications and other pipeline-related events.
The company's filings also record capital-structure matters involving common stock, pre-funded warrants and Series G warrants, along with shareholder voting results, board composition, committee appointments and governance items disclosed through annual-meeting and material-event reports.
iBio, Inc. (IBIO) disclosed that a director received a new stock option grant reported on Form 4. On 11/20/2025, the director was granted options to purchase 13,500 shares of iBio common stock at an exercise price of $1 per share. These options vest on a pro rata monthly basis over twelve months starting from the grant date, aligning the director’s compensation with the company’s share performance over the coming year. The options have an expiration date of 11/19/2035 and are held as direct ownership by the reporting person.
iBio, Inc. (IBIO) reported that one of its directors received a new stock option grant. On 11/20/2025, the director was granted options to purchase 13,500 shares of iBio common stock at an exercise price of $1.00 per share.
These options vest pro rata on a monthly basis over twelve months starting from the grant date, meaning the director earns a portion of the options each month during the first year. The options have an expiration date of 11/19/2035, giving a long period in which they may be exercised, subject to the vesting schedule and any applicable company or regulatory requirements.
iBio, Inc. reported a stock-based compensation grant to one of its directors. On 11/20/2025, the director received a stock option to purchase 13,500 shares of iBio common stock at an exercise price of $1.00 per share. The option becomes exercisable gradually, vesting in equal monthly installments over twelve months starting on the grant date, and expires on 11/19/2035 if not exercised. The filing indicates the director holds these options directly.
iBio, Inc. reported the results of its Annual Meeting of Stockholders held on November 20, 2025. Stockholders representing 10,566,364 shares were present in person or by proxy, constituting a quorum. Two Class II directors, Dr. Martin Brenner and Dr. Alexandra Kropotova, were elected to three-year terms expiring at the 2028 Annual Meeting.
Stockholders ratified the appointment of Grassi & Co., CPAs, P.C. as independent registered public accounting firm for the fiscal year ending June 30, 2026, with 9,912,837 votes for and 594,576 against. They also approved, on an advisory basis, the executive compensation program, with 4,392,583 votes for and 403,278 against.
In addition, stockholders approved holding future advisory votes on executive compensation every year, with 4,290,210 votes favoring a one-year frequency. Consistent with this vote and the Board’s recommendation, the Company will conduct an annual advisory say-on-pay vote until the next required vote on frequency.
iBio, Inc. filed a Form 8-K to announce that it has updated its corporate presentation. The new investor presentation is furnished as Exhibit 99.1 and is intended for use in meetings with investors, analysts and other stakeholders. The presentation includes forward-looking statements covered by “safe harbor” language under the Private Securities Litigation Reform Act of 1995. iBio notes it has no obligation to update the information in the presentation, although it may choose to do so through future public disclosures.
iBio, Inc. filed an amended Form 10-Q/A mainly to correct the CEO Section 906 certification language in Exhibit 32.1; all financial and business disclosures from the original quarterly report for the three months ended September 30, 2025 remain unchanged.
The company is a preclinical biotech using AI and machine learning to design precision antibodies for obesity and cardiometabolic diseases, with lead candidate IBIO-610, a long-acting Activin E–inhibiting antibody, targeted for first human trials in early 2027. For the quarter, iBio generated $100,000 of collaboration revenue and recorded a net loss of $5.7 million, or $0.11 per share, as R&D spending rose to support its pipeline. A recent underwritten public offering and related pre-funded warrants provided approximately $50 million of gross proceeds, lifting cash, cash equivalents and investments in debt securities to about $49.6 million, which management believes is sufficient to fund operations for at least 12 months from the filing date.
iBio, Inc. reported its quarterly results for the period ended September 30, 2025. The company generated $100,000 in revenue, with operating expenses of $6.1 million (R&D $3.6 million; G&A $2.5 million), leading to an operating loss of $5.95 million and a net loss of $5.72 million (loss per share $0.11).
Liquidity strengthened following an August 2025 financing, reflected in $28.1 million of cash and cash equivalents and $21.5 million of available‑for‑sale debt securities, totaling approximately $49.6 million at quarter‑end. Stockholders’ equity increased to $56.0 million. Shares outstanding were 20,254,599 as of September 30, 2025.
The company recognized collaboration revenue and reported contract liabilities of $1.15 million. iBio continues to build a preclinical pipeline focused on obesity and cardiometabolic diseases, with IBIO‑610 (Activin E) highlighted as a lead asset. Management states current liquidity is sufficient to fund operations for at least 12 months from the filing date.
iBio, Inc. filed a Form 8-K and furnished a press release announcing financial results for the quarter ended September 30, 2025. The disclosure appears under Item 2.02 (Results of Operations and Financial Condition) and the press release is included as Exhibit 99.1.
The company states this information is furnished, not filed, and it is not incorporated by reference into other SEC filings. The report is dated November 12, 2025.
iBio, Inc. reported it has regained compliance with Nasdaq Listing Rule 5550(a)(2) after receiving notice from Nasdaq on November 4, 2025. The rule requires a minimum closing bid price of $1.00 per share. The company had previously been notified on July 29, 2025 that it was out of compliance after its stock closed below $1.00 for 30 consecutive business days from June 13, 2025 to July 28, 2025. Nasdaq has indicated the matter is closed, supporting the company’s continued listing on The Nasdaq Capital Market.
iBio, Inc. announced new preclinical pharmacokinetic data for IBIO-610, a potentially first-in-class Activin E antibody. In obese non-human primates, IBIO-610 showed an extended half-life of 33.2 days. Using an allometric scaling model for half-life–extended antibodies, the company reports a predicted human half-life of up to 100 days, which could lower dosing to once every six months and improve patient experience.
The data will be presented by Cory Schwartz, Ph.D., during an oral session at ObesityWeek 2025 in Atlanta, held November 4–7, 2025. The announcement was shared via press release furnished with this report, which includes forward-looking statement disclosures.